Market Overview:
The global gastrointestinal drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of gastrointestinal diseases, rising geriatric population, and growing demand for prescription and over-the-counter (OTC) gastrointestinal drugs. The prescription gastrointestinal drug segment is expected to dominate the global market in terms of revenue during the forecast period. This segment is projected to grow at a CAGR of 5.8% from 2018 to 2030 due to an increase in the number of people suffering from chronic gastritis, functional dyspepsia, peptic ulcer, and other gastrointestinal diseases. The OTC gastrointestinal drug segment is projected grow at a higher rate than the prescription drug segment during the forecast period owing increased awareness about these drugs among consumers and an increase in distribution channels for these products.
Product Definition:
Gastrointestinal Drugs are medications that are used to treat disorders of the gastrointestinal system. This includes conditions such as constipation, diarrhea, and nausea. These drugs can help to relieve symptoms and improve quality of life for those affected by these conditions.
Prescription Gastrointestinal Drug:
Prescription gastrointestinal drug is a medication that is given to the patient for treating digestive disorders. The most common types of prescription drugs used to treat digestive diseases are antacids, anti-diarrheal, and anti-gas drugs. Other medications such as Imodium (Imodium AIT) and Kaopectate (Icopec) are also used in some cases.
OTC Gastrointestinal Drug:
OTC gastrointestinal drug is used for the treatment of various stomach disorders such as indigestion, heartburn, and acid reflux. OTC drugs are usually available in tablet or capsule form and can be administered to children as well. The global OTC gastrointestinal drug market was valued at USD 4.5 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period.
Application Insights:
The chronic gastritis segment dominated the global market in 2017. The growing geriatric population, coupled with increasing cases of lifestyle-induced diseases such as obesity and high blood pressure levels, is expected to be a major driving factor for this segment over the forecast period.
Functional dyspepsia is anticipated to be the fastest-growing application during the forecast period owing to rising awareness about gastroenteric drugs among healthcare professionals and patients. In addition, increasing incidences of Helicobacter pylori infection and nonalcoholic Steatohepatitis (NASH) are likely to contribute towards growth during this period. NASH is characterized by fatty liver degeneration with inflammation present in both alcoholic and nonalcoholic individuals; it has been estimated that up to 80% of patients suffering from diabetes may develop NASH over a span of 10 years.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of chronic diseases, such as functional gastrointestinal disorders and peptic ulcers. In addition, rising adoption of innovative therapies for treatment of these conditions is anticipated to drive regional growth over the forecast period.
Asia Pacific is expected to witness lucrative growth over the coming years owing to improving healthcare infrastructure and economic development in emerging countries like China and India. Furthermore, growing awareness about digestive health among consumers will also support regional market expansion during the same period.
Growth Factors:
- Increasing incidence of gastrointestinal diseases: The global incidence of gastrointestinal diseases is increasing due to the changing lifestyle and dietary habits. This is expected to drive the demand for gastrointestinal drugs in the coming years.
- Growing awareness about preventive measures: There is a growing awareness among people about preventive measures for gastrointestinal diseases. This is likely to boost the demand for gastrointestinal drugs in the near future.
- Technological advancements: The development of new and innovative technologies has led to the introduction of novel and advanced drugs for treating various types of gastrointestinal disorders. This is expected to create opportunities for growth in this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gastrointestinal Drugs Market Research Report
By Type
Prescription Gastrointestinal Drug, OTC Gastrointestinal Drug
By Application
Chronic Gastritis, Functional Dyspepsia, Peptic Ulcer, Acute Gastroenteritis, Other
By Companies
AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, Teva, Zeria(Tillotts), Perrigo, Boehringer Ingelheim, Purdue Pharma, C.B. Fleet, Abbott, Jiangzhong, Xian-Janssen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Gastrointestinal Drugs Market Report Segments:
The global Gastrointestinal Drugs market is segmented on the basis of:
Types
Prescription Gastrointestinal Drug, OTC Gastrointestinal Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Gastritis, Functional Dyspepsia, Peptic Ulcer, Acute Gastroenteritis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Sanofi
- Bayer
- Pfizer
- GlaxoSmithKline
- Teva
- Zeria(Tillotts)
- Perrigo
- Boehringer Ingelheim
- Purdue Pharma
- C.B. Fleet
- Abbott
- Jiangzhong
- Xian-Janssen
Highlights of The Gastrointestinal Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prescription Gastrointestinal Drug
- OTC Gastrointestinal Drug
- By Application:
- Chronic Gastritis
- Functional Dyspepsia
- Peptic Ulcer
- Acute Gastroenteritis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gastrointestinal Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gastrointestinal drugs are medications that are used to treat conditions that affect the stomach and intestines, such as gastroenteritis, peptic ulcers, and Crohn's disease.
Some of the key players operating in the gastrointestinal drugs market are AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, Teva, Zeria(Tillotts), Perrigo, Boehringer Ingelheim, Purdue Pharma, C.B. Fleet, Abbott, Jiangzhong, Xian-Janssen.
The gastrointestinal drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gastrointestinal Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gastrointestinal Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gastrointestinal Drugs Market - Supply Chain
4.5. Global Gastrointestinal Drugs Market Forecast
4.5.1. Gastrointestinal Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gastrointestinal Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gastrointestinal Drugs Market Absolute $ Opportunity
5. Global Gastrointestinal Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gastrointestinal Drugs Market Size and Volume Forecast by Type
5.3.1. Prescription Gastrointestinal Drug
5.3.2. OTC Gastrointestinal Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gastrointestinal Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gastrointestinal Drugs Market Size and Volume Forecast by Application
6.3.1. Chronic Gastritis
6.3.2. Functional Dyspepsia
6.3.3. Peptic Ulcer
6.3.4. Acute Gastroenteritis
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gastrointestinal Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gastrointestinal Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gastrointestinal Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gastrointestinal Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gastrointestinal Drugs Demand Share Forecast, 2019-2029
9. North America Gastrointestinal Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gastrointestinal Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gastrointestinal Drugs Market Size and Volume Forecast by Application
9.4.1. Chronic Gastritis
9.4.2. Functional Dyspepsia
9.4.3. Peptic Ulcer
9.4.4. Acute Gastroenteritis
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gastrointestinal Drugs Market Size and Volume Forecast by Type
9.7.1. Prescription Gastrointestinal Drug
9.7.2. OTC Gastrointestinal Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gastrointestinal Drugs Demand Share Forecast, 2019-2029
10. Latin America Gastrointestinal Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gastrointestinal Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gastrointestinal Drugs Market Size and Volume Forecast by Application
10.4.1. Chronic Gastritis
10.4.2. Functional Dyspepsia
10.4.3. Peptic Ulcer
10.4.4. Acute Gastroenteritis
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gastrointestinal Drugs Market Size and Volume Forecast by Type
10.7.1. Prescription Gastrointestinal Drug
10.7.2. OTC Gastrointestinal Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gastrointestinal Drugs Demand Share Forecast, 2019-2029
11. Europe Gastrointestinal Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gastrointestinal Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gastrointestinal Drugs Market Size and Volume Forecast by Application
11.4.1. Chronic Gastritis
11.4.2. Functional Dyspepsia
11.4.3. Peptic Ulcer
11.4.4. Acute Gastroenteritis
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gastrointestinal Drugs Market Size and Volume Forecast by Type
11.7.1. Prescription Gastrointestinal Drug
11.7.2. OTC Gastrointestinal Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gastrointestinal Drugs Demand Share, 2019-2029
12. Asia Pacific Gastrointestinal Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gastrointestinal Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gastrointestinal Drugs Market Size and Volume Forecast by Application
12.4.1. Chronic Gastritis
12.4.2. Functional Dyspepsia
12.4.3. Peptic Ulcer
12.4.4. Acute Gastroenteritis
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gastrointestinal Drugs Market Size and Volume Forecast by Type
12.7.1. Prescription Gastrointestinal Drug
12.7.2. OTC Gastrointestinal Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gastrointestinal Drugs Demand Share, 2019-2029
13. Middle East & Africa Gastrointestinal Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gastrointestinal Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gastrointestinal Drugs Market Size and Volume Forecast by Application
13.4.1. Chronic Gastritis
13.4.2. Functional Dyspepsia
13.4.3. Peptic Ulcer
13.4.4. Acute Gastroenteritis
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gastrointestinal Drugs Market Size and Volume Forecast by Type
13.7.1. Prescription Gastrointestinal Drug
13.7.2. OTC Gastrointestinal Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gastrointestinal Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Gastrointestinal Drugs Market: Market Share Analysis
14.2. Gastrointestinal Drugs Distributors and Customers
14.3. Gastrointestinal Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZeneca
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GlaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Zeria(Tillotts)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Perrigo
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Boehringer Ingelheim
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Purdue Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. C.B. Fleet
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Abbott
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Jiangzhong
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Xian-Janssen
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
